Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma, Large B-Cell, Diffuse 2Leukemia 2Waldenstrom Macroglobulinemia 1Paraproteinemias 1Neoplasms 1Lymphoproliferative Disorders 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Hemostatic Disorders 1Hematologic Diseases 1

Interventions

Dexamethasone 3Cyclophosphamide 3isatuximab 2Lenalidomide 2Bortezomib 2pomalidomide 1ofatumumab 1fludarabine phosphate 1fludarabine 1epratuzumab 1daratumumab 1birtamimab 1Whole-Body Irradiation 1Thalidomide 1Tacrolimus 1Ranitidine 1Mycophenolic Acid 1Melphalan 1Etoposide 1Doxorubicin 1Diphenhydramine 1Cisplatin 1Calcium Dobesilate 1CLR1404 1Acetaminophen 1ARQ 197 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Paraproteinemias × epratuzumab × Clear all
NCT00113802 2021-08-19

Study of Epratuzumab (hLL2) in Patients With Waldenstrom's Macroglobulinemia

Gilead Sciences

Phase 2 Terminated
31 enrolled
Lymphoid

Hematologic Diseases, Lymphoproliferative Disorders, Waldenstrom Macroglobulinemia, Paraproteinemias, Hemostatic Disorders

Data powered by HemOnc (CC BY 4.0) Colophon âš¡